DE69808274T2 - Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie - Google Patents

Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie

Info

Publication number
DE69808274T2
DE69808274T2 DE69808274T DE69808274T DE69808274T2 DE 69808274 T2 DE69808274 T2 DE 69808274T2 DE 69808274 T DE69808274 T DE 69808274T DE 69808274 T DE69808274 T DE 69808274T DE 69808274 T2 DE69808274 T2 DE 69808274T2
Authority
DE
Germany
Prior art keywords
disorganizes
nucleic acid
extracellular matrix
gene therapy
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69808274T
Other languages
English (en)
Other versions
DE69808274D1 (de
Inventor
Serge Braun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Association Francaise Contre les Myopathies
Original Assignee
Transgene SA
Association Francaise Contre les Myopathies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA, Association Francaise Contre les Myopathies filed Critical Transgene SA
Publication of DE69808274D1 publication Critical patent/DE69808274D1/de
Application granted granted Critical
Publication of DE69808274T2 publication Critical patent/DE69808274T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69808274T 1997-05-29 1998-05-29 Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie Expired - Lifetime DE69808274T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9706600A FR2763958A1 (fr) 1997-05-29 1997-05-29 Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
PCT/FR1998/001084 WO1998053853A1 (fr) 1997-05-29 1998-05-29 Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique

Publications (2)

Publication Number Publication Date
DE69808274D1 DE69808274D1 (de) 2002-10-31
DE69808274T2 true DE69808274T2 (de) 2003-05-15

Family

ID=9507375

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69808274T Expired - Lifetime DE69808274T2 (de) 1997-05-29 1998-05-29 Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie

Country Status (12)

Country Link
US (1) US6258791B1 (de)
EP (1) EP0980263B1 (de)
JP (1) JP2002500662A (de)
AT (1) ATE224736T1 (de)
AU (1) AU752146B2 (de)
CA (1) CA2291590A1 (de)
DE (1) DE69808274T2 (de)
DK (1) DK0980263T3 (de)
ES (1) ES2181234T3 (de)
FR (1) FR2763958A1 (de)
PT (1) PT980263E (de)
WO (1) WO1998053853A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0998945A1 (de) * 1998-09-30 2000-05-10 Transgene S.A. Verwendung von Magnesium (Mg2+) zur Erhöhung der Gen-Verabreichung bei Gentherapie
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
WO2000034500A2 (en) * 1998-12-04 2000-06-15 Genzyme Corporation Methods for increasing the efficiency of gene transfer
US6719986B1 (en) * 1998-12-23 2004-04-13 Esparma Gmbh Hyaluronate lyase used for promoting penetration in topical agents
IL152420A0 (en) * 2001-02-23 2003-05-29 Novartis Ag Novel oncolytic adenoviral vectors
JP2005524389A (ja) * 2001-11-26 2005-08-18 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 宿主組織内への核酸分子の電気的遺伝子導入の増強
WO2003070256A1 (en) * 2002-02-15 2003-08-28 Research Development Foundation Hyaluronic acid mediated adenoviral transduction
DE10211457A1 (de) * 2002-03-12 2003-09-25 Knoell Hans Forschung Ev Verwendung von Hyaluronatlyase zur Behandlung von Myokardinfarkten
EP1521523A4 (de) * 2002-05-20 2006-04-19 Univ Texas Verfahren und zusammensetzungen zur zuführung von enzymen und nukleinsäuremolekülen an gehirn, knochen und andere gewebe
WO2004098534A2 (en) * 2003-02-24 2004-11-18 Therion Biologics Corporation Methods for delivering angiogenic modulators using pox viruses
JP4464395B2 (ja) * 2003-03-05 2010-05-19 ヘイローザイム インコーポレイテッド 可溶性ヒアルロニダーゼ糖タンパク質（ｓＨＡＳＥＧＰ）、その調製プロセス、使用およびそれを含む薬学的組成物
US20050014714A1 (en) * 2003-06-04 2005-01-20 The Johns Hopkins University Gene delivery to organs
AU2004263274B2 (en) 2003-07-21 2009-11-05 Transgene S.A. Novel multifunctional cytokines
US7888201B2 (en) * 2003-11-04 2011-02-15 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor-on-insulator SRAM configured using partially-depleted and fully-depleted transistors
US7572613B2 (en) * 2004-06-25 2009-08-11 Klein Jeffrey A Drug delivery system for accelerated subcutaneous absorption
JP2007175021A (ja) * 2005-12-28 2007-07-12 Sysmex Corp 大腸がんのリンパ節転移マーカー
JP2010519211A (ja) * 2007-02-15 2010-06-03 アラーガン、インコーポレイテッド 膀胱もしくは前立腺障害または多汗症を処置するためのボツリヌス毒素および酵素の使用
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
WO2010138918A1 (en) * 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
US10610486B2 (en) 2010-10-28 2020-04-07 Pacira Pharmaceuticals, Inc. Sustained release formulation of a non-steroidal anti-inflammatory drug
US9657076B2 (en) 2012-10-23 2017-05-23 Emory University GM-CSF and IL-4 conjugates, compositions, and methods related thereto
CN110418650A (zh) 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
WO2018094253A1 (en) 2016-11-18 2018-05-24 Pacira Pharmaceuticals, Inc. Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same
US11203629B2 (en) 2017-04-22 2021-12-21 Immunomic Therapeutics, Inc. LAMP constructs
AU2018263923A1 (en) 2017-05-02 2019-10-31 Immunomic Therapeutics, Inc. LAMP (lysosomal associated membrane protein) constructs comprising cancer antigens
WO2019222281A1 (en) 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc Improved lamp constructs comprising allergens
CA3153850A1 (en) 2019-10-18 2021-04-22 Teri Heiland Improved lamp constructs comprising cancer antigens
US20220401583A1 (en) * 2021-06-16 2022-12-22 BioViva USA, Inc. Treatment of age-related cognitive decline using genetically modified viral vectors
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7312891A (en) * 1990-02-12 1991-09-03 Board Of Regents, The University Of Texas System Satellite cell proliferation in adult skeletal muscle
US5616483A (en) * 1992-06-11 1997-04-01 Aktiebolaget Astra Genomic DNA sequences encoding human BSSL/CEL
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
FR2732895B1 (fr) 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US6177410B1 (en) 1997-12-05 2001-01-23 Vanderbilt University Therapeutic methods for prostate cancer

Also Published As

Publication number Publication date
CA2291590A1 (fr) 1998-12-03
ES2181234T3 (es) 2003-02-16
US6258791B1 (en) 2001-07-10
EP0980263A1 (de) 2000-02-23
DE69808274D1 (de) 2002-10-31
AU8023898A (en) 1998-12-30
AU752146B2 (en) 2002-09-05
ATE224736T1 (de) 2002-10-15
WO1998053853A1 (fr) 1998-12-03
FR2763958A1 (fr) 1998-12-04
DK0980263T3 (da) 2003-02-03
JP2002500662A (ja) 2002-01-08
EP0980263B1 (de) 2002-09-25
PT980263E (pt) 2003-02-28

Similar Documents

Publication Publication Date Title
ATE224736T1 (de) Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie
ATE367448T1 (de) Zusammensetzung enthaltend nukleinsäuren und kationische polymere, zubereitung und verwendung
BR9915597A (pt) Amplificação multiplex de loci repetidos em tandem curtos
ATE266723T1 (de) Lösung die chaotropische mittel enthält und verwendung dieser lösung in verfahren zur isolierung von dna, rna und proteinen
ATE373672T1 (de) Synthese von methoxynukleoside und enzymatische nukleisäure moleküle
ZA200405390B (en) Entrapped binding proteins as biosensors
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
UA74325C2 (uk) ГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ р38, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЇХ МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ ЗА ЇХ ДОПОМОГОЮ
BR0210593A (pt) polinucleotìdeos de defensina e métodos de uso
AU2001268468A1 (en) Use of nucleotide analogs in the analysis of oligonucleotide mixtures and in highly multiplexed nucleic acid sequencing
PT1053256E (pt) Anticorpos para o receptor de morte 4 (dr4) e utilizações destes
DE69732535D1 (de) Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression
DE60235005D1 (de) Nachweis der instabilität von mikrosatelliten und
DE69828045D1 (de) Verbindungen, ihre herstellung und ihre verwendung für den transfer von nucleinsäuren in zellen
EP1123414A4 (de) Antisense modulation der expression von integrin alpha 4
WO2000030667A3 (en) Compositions and methods using lactadherin or variants thereof
ATE305037T1 (de) Peptide, die fähig sind die sh3-domäne des gap- proteins zu binden, ihre kodierende dns, ihre zubereitung und verwendung
ATE291621T1 (de) Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen
ATE474047T1 (de) Nukleinsäuremolekül, die für die alpha-kettedes pferde-fc-epsilon-rezeptors kodieren, korrespondierende proteine und ihre verwendungen
ATE263239T1 (de) Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2)
DE69613984D1 (de) Für die protein-kinase a-spezifische modifizierte oligonukleotide und verfahren zur deren verwendung
HUP0101393A1 (hu) Redukáló körülményekre érzékeny transzfektáló kompozíciók, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE275207T1 (de) Dna zur abschätzung des progressionspotentials von zervixläsionen
AU6722498A (en) Disubstituted biphenyloxazolines
HUP0102455A2 (hu) Új nukleinsav-transzfer ágensek, ezeket tartalmazó készítmények és alkalmazásuk

Legal Events

Date Code Title Description
8364 No opposition during term of opposition